Tesamorelin + Ipamorelin Blend Research: DEXA Scan Notes

DEXA — dual-energy X-ray absorptiometry — is the body-composition method most frequently referenced in published research on growth-hormone-axis compounds, which is why DEXA scan notes come up alongside tesamorelin and ipamorelin in research discussion. For a business buyer, the operative point is not the endpoint itself but the material behind it: body-composition data is only as interpretable as the identity, purity and batch documentation of the compound studied. Tesamorelin and ipamorelin are distinct molecules acting at distinct receptor targets, and a pre-mixed blend is a commercial format that makes per-component verification harder, not simpler. Real Peptides stocks single-compound research vials with batch-matched, publicly viewable certificates of analysis — the format that keeps a research record clean and auditable. All compounds are supplied for laboratory research use only.

Two molecules, two receptor targets, one axis

Tesamorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH), a hypothalamic peptide that acts on pituitary GHRH receptors. Ipamorelin is a selective growth hormone secretagogue that research characterises as acting at the ghrelin receptor (GHS-R1a). Studies indicate the two engage different receptor families that converge on the same somatotropic signalling axis, which is the mechanistic reason researchers describe them together in the literature at all. That is a statement about receptor pharmacology, not a performance claim, and nothing in the published record should be read as a promise of any particular measurable outcome.

The published body of work behind each compound is also shaped differently. Research involving tesamorelin has commonly used imaging-based body-composition endpoints, including regional adipose measures. Ipamorelin's literature leans more heavily toward preclinical and mechanistic models. A buyer evaluating catalog demand should understand that these are not interchangeable evidence bases, and a supplier who markets them as a single story is selling narrative rather than chemistry.

The physicochemical differences matter commercially. The two peptides differ in sequence length, molecular weight, solubility behaviour and hygroscopicity. Co-lyophilising two peptides with different handling profiles into one vial is a formulation decision with real consequences for stability, reconstitution behaviour and analytical testing. When a vendor offers a blend, the first question is whether that formulation was developed and validated, or simply weighed together because it sells.

What a DEXA record can and cannot support

DEXA estimates three compartments — bone mineral content, lean soft tissue and fat mass — using differential attenuation of two X-ray energies. In the research literature it is valued for regional segmentation: the method reports trunk, limb and whole-body values rather than a single number. That regional capability is exactly why it appears in body-composition research notes.

Its limits are equally well documented and equally relevant. DEXA does not cleanly separate visceral adipose tissue from subcutaneous abdominal fat; research that specifically targets visceral compartments generally relies on cross-sectional imaging such as CT or MRI instead. DEXA estimates are also sensitive to soft-tissue hydration, scanner model, software version and calibration state. Results from two different machines, or from the same machine after a software revision, are not freely interchangeable, which is why careful research notes record device, software build, calibration log and operator alongside the values themselves.

For anyone reading research summaries as part of a sourcing decision, three habits are worth adopting. First, check whether reported changes exceed the stated precision error of the instrument, because small differences can sit inside measurement noise. Second, check whether the comparison is within-subject on one scanner or pooled across sites. Third, check whether the compound studied was characterised at all — many summaries circulating in the industry cite endpoints without identifying the source, purity or lot of the material used. A DEXA value attached to an uncharacterised peptide is a number without a denominator.

None of this is guidance for administration. It is methodology context, and it belongs in a research file rather than a service description.

Why a blended vial complicates the paper trail

Analytical verification is where blends quietly fail business buyers. HPLC run on a single peptide yields one principal peak and a purity figure that means something specific: the proportion of total peak area attributable to the target molecule. Run the same method on a two-peptide mixture and the output is ambiguous. Is a stated purity figure the sum of both components? The purity of the dominant one? Does it account for the ratio actually present in the vial, or only for the absence of unrelated impurities?

A defensible blend COA therefore has to do more work than a single-compound COA, not less. It needs per-component identity confirmation — mass spectrometry establishing that each molecular weight present is the one claimed — plus a content or ratio assay demonstrating the proportion in the finished vial, plus the usual impurity and residual testing applied to the mixture as a whole. In practice, blend documentation circulating in the wholesale market is frequently thinner than single-compound documentation, which is the opposite of what the chemistry requires.

There are operational consequences too. Co-lyophilised peptides share a stability fate: if one component degrades faster under the same storage conditions, the ratio drifts and the lot's characterisation stops describing what is in the vial. Lot-level risk concentrates rather than diversifies — an out-of-spec result on one component condemns the entire blended batch, including the component that was fine. And a blend removes a variable from the research design itself. A laboratory that wants to vary one compound while holding the other constant cannot do that from a fixed-ratio vial.

For a reseller or clinic operator building a catalog, single-compound sourcing keeps both the documentation and the inventory flexible. Buyers who want both compounds on the shelf can stock Tesamorelin 10mg and Ipamorelin 10mg as separate line items, each with its own batch record, its own expiry tracking and its own verifiable COA.

How to read a certificate of analysis before you commit to a lot

The single most useful discipline in wholesale peptide buying is refusing to treat a COA as a formality. Documents vary enormously in what they actually establish, and several common industry practices — publishing purity without identity, selling COAs as a paid add-on, or claiming third-party testing without producing the third party's report — survive only because buyers do not read closely.

Two cross-checks matter more than any single row. The batch number on the COA must match the batch number printed on the vial you received, not a representative lot. And the document should be accessible without a sales conversation — a supplier who publishes lab results openly is inviting scrutiny, which is the behaviour you want from a partner whose material ends up under your brand.

Compliance questions worth answering before the first order

This section is informational and is not legal advice. The regulatory position of research-use-only compounds is not something a supplier's blog can settle for you, and any page that tells you flatly what is or is not permitted in your jurisdiction is overreaching.

The productive move is to bring your attorney and, where relevant, your state licensing board a specific list of questions. What does your business licence permit you to purchase, hold and resell? How must research-use-only material be labelled, stored and segregated from anything else you carry? What record-keeping is expected of a reseller, and for how long? Are there state-level registration or permitting questions that attach to your entity type rather than to the compound? If you operate a licensed facility, what does your board expect regarding materials held on site that are not approved drugs? These questions generally have answers — but the answers are jurisdiction-specific, change over time, and belong to your counsel rather than to a vendor.

Two standing boundaries apply regardless. Research compounds are not FDA-approved drugs and are not supplied for human or animal consumption. And if any animal-adjacent question ever reaches your desk, talk to your veterinarian before acting on it — research-use material is not a veterinary product, and that conversation should happen with a licensed professional rather than a supplier.

What Real Peptides does differently

Real Peptides builds the Wholesale Partner Program around verification rather than persuasion. Every compound in the catalog is tested to 99%+ HPLC purity, and every batch goes through 7-panel testing before release. The resulting certificates of analysis are publicly verifiable — a prospective buyer can look up lab results independently, before committing to a purchase order and without paying for access or requesting them through a representative. That is deliberate: documentation that only appears after a deposit is documentation that cannot be used to make the buying decision.

Fulfilment is handled domestically, with US shipping in 5–7 days, which keeps inventory planning predictable for operators who cannot afford open-ended lead times on a catalog line. The Wholesale Partner Program itself runs through a straightforward 3-step application rather than an extended qualification process, and pricing is presented to approved partners rather than hidden behind an indefinite negotiation. Margin structure, order volumes and category mix vary widely between businesses, so those figures are discussed against your actual catalog rather than advertised as a universal promise.

What Real Peptides does not do is equally relevant. It does not market pre-mixed blends as a shortcut around per-component verification, and it does not frame research compounds as therapeutics. Growth-hormone-axis research compounds sit alongside the rest of the catalog as single-compound, batch-documented line items.

Where qualified buyers go from here

If you operate a med spa, clinic, telehealth company or reseller brand and you are evaluating growth-hormone-axis research compounds for your catalog, the path is the Wholesale Partner Program application at Real Peptides. Review the published COAs for the specific lots on offer first, confirm the documentation answers the questions in the table above, and bring your compliance questions to your own counsel in parallel. A supplier relationship that starts with verifiable paperwork is the only kind worth building a catalog on.

Buyers researching adjacent compounds can review CJC-1295 No DAC 10mg and AOD-9604 as separately documented catalog items, or browse the broader growth factor and tissue signaling research and mitochondrial and metabolic pathway research collections to see how batch documentation is handled across the catalog.